MSD

MK6482

Biodrugs/ Drugs
Cancer
MK-6482 Versus Everolimus in Participants With Advanced Renal Cell Carcinoma That has Progressed After Prior PD-1/L1 and VEGF-Targeted Therapies.
3Phase III in Spain, 2Phase II, 1Phase I